Market Research Logo

Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023

Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023

“The global real world evidence market projected to grow at a CAGR of 14.3%.”
The global real-world evidence market is projected to reach USD 1,348.1 million by 2023 from USD 689.9 million in 2018, at a CAGR of 14.3% during the forecast period. The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs). However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection are restraining the growth of this market.

“The services segment is expected to register the highest CAGR during the forecast period.”
On the basis of component, the real world evidence market is segmented into data sets and services. The services segment is expected to register the highest CAGR during the forecast period. The high growth rate of this segment is mainly due to the rising need to convert data into actionable evidence, growing need to reduce drug development delays, and availability of large amounts of healthcare data are the major factors driving market growth in this segment.

“Pharmaceutical & medical device companies segment expected to grow at the highest CAGR during 2018 to 2023.”
Based on end user, the real-world evidence (RWE) market is broadly segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users (academic institutions, patient advocacy groups, and health technology assessment agencies). The pharmaceutical & biopharmaceutical companies segment is the fastest-growing segment in the real world evidence market during the forecast period. The rising demand to assess comparative effectiveness of drugs in actual, real-world use and the value or economic impact from the use of new or existing drugs are the major factors driving the growth of the real world evidence market for pharmaceutical & medical device companies.

“APAC is projected to witness the highest growth during the forecast period.”
North America held the largest share of the global real world evidence market in 2017. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, due to the increasing government initiatives for the adoption of RWE studies, rising burden of chronic diseases, increasing demand for better healthcare services, and the rising geriatric population in the Asia Pacific region.

Break of primary participants was as mentioned below:
By Company Type - Tier 1-25%, Tier 2-50% and Tier 3-25%
By Designation - C-level-25%, Director Level-37%, Others-38%
By Region - North America-25%, Europe-25%, Asia Pacific-37%, Rest of World-13%

The prominent players in the global real world evidence market are IQVIA (US), International Business Machines Corporation (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

Research Coverage:
The report analyzes the various real world evidence and their adoption pattern. It aims at estimating the market size and future growth potential of the global real world evidence market for different segments such as by component, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.

This report provides insights on the following pointers:
Market Penetration: Comprehensive information on product portfolios offered by the top players in the global real world evidence market. The report analyzes the global real world evidence market by component, therapeutic area, end user, and region
Service Development/Innovation: Detailed insights on upcoming trends and service launches in the global real world evidence market
Market Development: Comprehensive information on the lucrative emerging regions by component, therapeutic area, end user, and region
Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global real world evidence market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and services of leading players in the global real world evidence market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
      • MARKETS COVERED
    • YEARS CONSIDERED FOR THE STUDY
    • LIMITATIONS
    • CURRENCY
      • Table STANDARD CURRENCY CONVERSION RATES
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • RESEARCH APPROACH
      • SECONDARY DATA
      • PRIMARY DATA
    • MARKET SIZE ESTIMATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • REAL-WORLD EVIDENCE: MARKET OVERVIEW
    • EUROPE REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA AND COUNTRY
    • REAL-WORLD EVIDENCE MARKET: GEOGRAPHIC SNAPSHOT
    • REAL-WORLD EVIDENCE: GEOGRAPHIC MIX
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • DRIVERS
        • Table DRIVERS: IMPACT ANALYSIS
      • RESTRAINTS
        • Table RESTRAINTS: IMPACT ANALYSIS
      • OPPORTUNITIES
        • Table OPPORTUNITIES: IMPACT ANALYSIS
      • CHALLENGES
        • Table CHALLENGES: IMPACT ANALYSIS
  • INDUSTRY TRENDS
    • INDUSTRY TRENDS
      • EMERGING ROLE OF WEARABLE DEVICES
      • SOCIAL MEDIA SOURCED REAL-WORLD EVIDENCE
      • INCORPORATION OF ARTIFICIAL INTELLIGENCE IN REAL-WORLD DATA MANAGEMENT
    • REAL-WORLD DATA SOURCES
      • Table INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES
  • REAL-WORLD EVIDENCE MARKET, BY COMPONENT
    • INTRODUCTION
      • Table REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
    • DATA SETS
      • Table REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
      • Table REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
      • CLINICAL SETTINGS DATA
        • Table REAL-WORLD EVIDENCE CLINICAL SETTINGS DATA MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
      • CLAIMS DATA
        • Table REAL-WORLD EVIDENCE CLAIMS DATA MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
      • PHARMACY DATA
        • Table REAL-WORLD EVIDENCE PHARMACY DATA MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
      • PATIENT-POWERED DATA
        • Table REAL-WORLD EVIDENCE PATIENT-POWERED DATA MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
    • SERVICES
      • Table REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA
    • INTRODUCTION
      • Table REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
    • ONCOLOGY
      • Table REAL-WORLD EVIDENCE MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
    • CARDIOVASCULAR DISEASE
      • Table REAL-WORLD EVIDENCE MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2016-2023 (USD MILLION)
    • NEUROLOGY
      • Table REAL-WORLD EVIDENCE MARKET FOR NEUROLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
    • IMMUNOLOGY
      • Table REAL-WORLD EVIDENCE MARKET FOR IMMUNOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
    • OTHER THERAPEUTIC AREAS
      • Table REAL-WORLD EVIDENCE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2016-2023 (USD MILLION)
  • REAL-WORLD EVIDENCE MARKET, BY END USER
    • INTRODUCTION
      • Table REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
    • PHARMACEUTICAL & MEDICAL DEVICE COMPANIES
      • Table REAL-WORLD EVIDENCE MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2016-2023 (USD MILLION)
    • HEALTHCARE PAYERS
      • Table REAL-WORLD EVIDENCE MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2016-2023 (USD MILLION)
    • HEALTHCARE PROVIDERS
      • Table REAL-WORLD EVIDENCE MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2016-2023 (USD MILLION)
    • OTHER END USERS
      • Table REAL-WORLD EVIDENCE MARKET FOR OTHER END USERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • REAL-WORLD EVIDENCE MARKET, BY REGION
    • INTRODUCTION
      • Table REAL-WORLD EVIDENCE MARKET, BY REGION, 2016-2023 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
      • Table NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
      • Table NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
      • Table NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
      • Table NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • US
        • Table US: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table US: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table US: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • CANADA
        • Table CANADA: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table CANADA: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table CANADA: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
    • EUROPE
      • Table EUROPE: REAL-WORLD EVIDENCE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
      • Table EUROPE: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
      • Table EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
      • Table EUROPE: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
      • Table EUROPE: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • GERMANY
        • Table GERMANY: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table GERMANY: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table GERMANY: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • UK
        • Table UK: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table UK: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table UK: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • FRANCE
        • Table FRANCE: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table FRANCE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table FRANCE: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table FRANCE: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • ITALY
        • Table ITALY: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table ITALY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table ITALY: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table ITALY: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • SPAIN
        • Table SPAIN: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table SPAIN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table SPAIN: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table SPAIN: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • REST OF EUROPE
        • Table ROE: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table ROE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table ROE: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table ROE: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
    • ASIA PACIFIC
      • Table ASIA PACIFIC: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
      • Table ASIA PACIFIC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
      • Table ASIA PACIFIC: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
      • Table ASIA PACIFIC: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • JAPAN
        • Table JAPAN: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table JAPAN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table JAPAN: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table JAPAN: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • CHINA
        • Table CHINA: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table CHINA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table CHINA: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table CHINA: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
      • REST OF APAC
        • Table ROAPAC: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
        • Table ROAPAC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
        • Table ROAPAC: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
        • Table ROAPAC: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
    • REST OF THE WORLD
      • Table ROW: REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016-2023 (USD MILLION)
      • Table ROW: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2016-2023 (USD MILLION)
      • Table ROW: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
      • Table ROW: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016-2023 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
      • Table GROWTH STRATEGY MATRIX (2014-2018)
    • COMPETITIVE SCENARIO
      • MERGERS & ACQUISITIONS
        • Table ACQUISITIONS, 2014-2018
      • PARTNERSHIPS, AGREEMENTS, ALLIANCES, AND COLLABORATIONS
        • Table PARTNERSHIPS, AGREEMENTS, ALLIANCES, AND COLLABORATIONS, 2014-2017
      • SERVICES LAUNCHES
        • Table SERVICE LAUNCHES, 2014-2017
  • COMPANY PROFILES
    • IQVIA
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • IBM
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • PHARMACEUTICAL PRODUCT DEVELOPMENT
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • PAREXEL
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • OPTUM (A SUBSIDIARY OF UNITED HEALTH GROUP, INC.)
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • PERKINELMER
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ICON PLC
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ORACLE
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • COGNIZANT
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • MNM VIEW
    • SYNEOS HEALTH
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ANTHEM
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • CLINIGEN
      • BUSINESS OVERVIEW
      • SERVICES OFFERED
      • MNM VIEW
    • SAS INSTITUTE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENT
      • MNM VIEW
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report